9 results
P
dilated cardiomyopathy patients
I/C
atorvastatin treatment, control groups
O
left ventricular ejection fraction, 6-minute walk test, N-terminal pro-brain natriuretic peptide, left ventricular systolic volume, low-density lipoprotein, C-reactive protein
P
Patients with dyslipidemia
I/C
High-dose atorvastatin (80 mg), Other therapies
O
Reduced risk of Major Cardiovascular Events (MACE), mortality, and adverse events
P
51956 participants
I/C
7 different statins (simvastatin, fluvastatin, atorvastatin, rosuvastatin, lovastatin, pravastatin, and pitavastatin), comparing the lipid-lowering efficacy of no less than two of the included statins (or statin vs. placebo)
O
LDL-C lowering
P
animal models
I/C
calcium phosphate carried simvastatin, cloth or calcium phosphate alone
O
bone formation and regeneration
P
patients with relapsing-remitting MS (RRMS), patients with secondary-progressive MS (SPMS), patients with clinically isolated syndrome (CIS), patients with optic neuritis (ON)
I/C
statins, add-on statin use, stand-alone simvastatin, non-statin-treated patients, IFN-β
O
clinical relapse, EDSS-progression, new contrast-enhancing or T2 lesions, whole-brain volume reduction, annualized rate of whole-brain volume reduction, new T2 lesions, visual recovery
P
statin users, nonusers
I/C
use of statins, nonusers
O
development of hepatocellular carcinoma
P
hypercholesterolemia adults
I/C
combination therapy with ezetimibe and statins (E/S), double dose of statin (D/S) monotherapy, ezetimibe and statins vs. double dose of statin
O
low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), high-density lipoprotein (HDL)
P
24,365
I/C
statins, heterozygote, homozygote
O
LDL-C-lowering effectiveness, HDL-C-increasing effectiveness, TC-reducing effectiveness